The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.
Combining topical minoxidil and pyrilutamide (KX-826) for hair loss treatment. It is suggested to apply minoxidil first, wait 20 minutes, then apply pyrilutamide for better absorption.
A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.
A $3 hair oil applicator is recommended for applying minoxidil efficiently, reducing wastage and oily scalp issues. Users discuss cleaning methods and price differences.
A user plans to order Pyrilutamide for hair loss after losing ground on finasteride. Another user advises against buying from Hairliciously, suggesting Amazon instead.
Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.
Using a microdose of finasteride on the scalp with minoxidil as a carrier may have positive effects with minimal side effects. The user is also considering the effects of sulforaphane or broccoli sprouts on hair loss.
A 24-year-old experiencing severe hair thinning has been using minoxidil for 2 years but is still shedding hair. A doctor recommended plasma treatment over a DHT blocker for better and healthier results.
The conversation is about Kintor's announcement indicating continued hope for their product KX-826 as a treatment for Alopecia Androgenetica. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The user experienced improved hair health and density after three months using 1mg finasteride and topical minoxidil twice daily, with no side effects. They also use ketoconazole 2% twice weekly and purchase their medications from Amazon.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
OrganTech is working on regenerating hair and teeth, with positive results in mice, but skepticism remains about progress for humans. Users express frustration over the lack of advancements in human hair loss treatments, despite ongoing research and trials.
Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."
The conversation discusses the legitimacy of purchasing Pyrilutamide (KX-826) for hair loss treatment. Users mention using Minoxidil and express interest in waiting for phase 3 trials for safety and efficacy confirmation.
The conversation is about using topical tazarotene with minoxidil for hair loss treatment. A user suggests using a lower strength than 0.025% for daily application.
A user shared their positive 3-month results using a treatment for hair loss that includes Dermaroller, Minoxidil, and Amplexe Shampoo. They avoided using finasteride due to its risks.
Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.
Green tea extract combined with red light therapy is being considered for hair growth on the scalp. Traditional treatments like finasteride, dutasteride, and minoxidil are also mentioned.
Low-level laser therapy (LLLT) is debated for hair regrowth, with some users suggesting it should be combined with treatments like minoxidil and finasteride for effectiveness. Many users express skepticism about LLLT's efficacy and cost, emphasizing the need for the correct wavelength and quality devices.
A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.